Suppr超能文献

相似文献

1
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
2
Staging systems of hepatocellular carcinoma: A review.
Indian J Gastroenterol. 2018 Nov;37(6):481-491. doi: 10.1007/s12664-018-0915-0. Epub 2018 Dec 29.
5
The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma.
Rev Esp Enferm Dig. 2012 Jun;104(6):298-304. doi: 10.4321/s1130-01082012000600003.
6
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327.
9
BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A.
J Gastroenterol Hepatol. 2016 Feb;31(2):467-74. doi: 10.1111/jgh.13152.
10
Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients.
Liver Int. 2015 Feb;35(2):591-600. doi: 10.1111/liv.12696. Epub 2014 Oct 31.

引用本文的文献

1
Responsive biomaterials for therapeutic strategies of hepatocellular carcinoma.
Front Bioeng Biotechnol. 2025 Aug 20;13:1673134. doi: 10.3389/fbioe.2025.1673134. eCollection 2025.
2
Metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges in clinical practice.
Clin Exp Hepatol. 2025 Jun;11(2):105-112. doi: 10.5114/ceh.2025.151618. Epub 2025 Jun 9.
3
Modern approach to hepatocellular carcinoma treatment.
World J Hepatol. 2025 Aug 27;17(8):107873. doi: 10.4254/wjh.v17.i8.107873.
5
The synergistic potential of camrelizumab and rivoceranib in advanced hepatocellular carcinoma: a review of current evidence.
Ann Med Surg (Lond). 2025 Jul 18;87(9):5598-5606. doi: 10.1097/MS9.0000000000003597. eCollection 2025 Sep.
8
Tumor burden score and borderline resectability criteria as predictors of survival in advanced hepatocellular carcinoma.
Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):630-633. doi: 10.21037/hbsn-2025-312. Epub 2025 Jul 23.

本文引用的文献

1
Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.
Nat Cancer. 2021 Sep;2(9):891-903. doi: 10.1038/s43018-021-00234-4. Epub 2021 Jul 29.
2
Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
J Hepatol. 2022 Feb;76(2):458-463. doi: 10.1016/j.jhep.2021.09.029. Epub 2021 Oct 2.
3
Methods of Public Health Research - Strengthening Causal Inference from Observational Data.
N Engl J Med. 2021 Oct 7;385(15):1345-1348. doi: 10.1056/NEJMp2113319. Epub 2021 Oct 2.
4
MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era.
Gastroenterology. 2021 Dec;161(6):1887-1895.e4. doi: 10.1053/j.gastro.2021.08.050. Epub 2021 Sep 3.
6
Systemic treatment of hepatocellular carcinoma: An EASL position paper.
J Hepatol. 2021 Oct;75(4):960-974. doi: 10.1016/j.jhep.2021.07.004. Epub 2021 Jul 10.
7
Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
J Hepatol. 2021 Nov;75(5):1154-1163. doi: 10.1016/j.jhep.2021.06.015. Epub 2021 Jun 22.
8
Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit?
Clin Liver Dis. 2021 Feb;25(1):19-33. doi: 10.1016/j.cld.2020.08.002. Epub 2020 Oct 17.
9
Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
Hepatology. 2021 Nov;74(5):2342-2352. doi: 10.1002/hep.31819. Epub 2021 Jun 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验